Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Resiquimod Sulfate

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Resiquimod sulfate (usan), 2762439-40-5, Resiquimod sulfate [usan], Eik1001 sulfate, Eik-1001 sulfate, C8fkis4p1n
    Molecular Formula
    C17H24N4O6S
    Molecular Weight
    412.5  g/mol
    InChI Key
    DGMINEMBFOEPHX-UHFFFAOYSA-N
    FDA UNII
    C8FKIS4P1N
    Resiquimod Sulfate is the sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, with potential immunostimulating and antineoplastic activities. Upon administration, resiquimod targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol;sulfuric acid
    2.1.2 InChI
    InChI=1S/C17H22N4O2.H2O4S/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18;1-5(2,3)4/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19);(H2,1,2,3,4)
    2.1.3 InChI Key
    DGMINEMBFOEPHX-UHFFFAOYSA-N
    2.2 Other Identifiers
    2.2.1 UNII
    C8FKIS4P1N
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Resiquimod Sulfate (usan)

    2. 2762439-40-5

    3. Resiquimod Sulfate [usan]

    4. Eik1001 Sulfate

    5. Eik-1001 Sulfate

    6. C8fkis4p1n

    7. Bdb001

    8. Bdb 001 [who-dd]

    9. Bdb-001

    10. C151008135d

    11. C151008135-d

    12. D13051

    13. 4-amino-2-(ethoxymethyl)-1-(2-hydroxisobutyl) Imidazo[4,5-c]quinoline, Sulfate (1:1)

    14. 1h-imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-, Sulfate (1:1)

    2.4 Create Date
    2025-02-20
    3 Chemical and Physical Properties
    Molecular Weight 412.5 g/mol
    Molecular Formula C17H24N4O6S
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count5
    Exact Mass Da
    Monoisotopic Mass Da
    Topological Polar Surface Area169
    Heavy Atom Count28
    Formal Charge0
    Complexity487
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Pharmacology and Biochemistry
    4.1 Mechanism of Action

    BDB-001 is an anti-C5RA1 monoclonal antibody activating the toll-like receptor. It has potential antineoplastic and immunostimulating activities.

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.